SueWallSt

Dive into the NuScale Power $SMR controversy as we break down a high stakes securities class action involving nuclear energy, small modular reactors, and alleged misleading disclosures about key partner ENTRA1. This episode is for investors, traders, and anyone following energy stocks, clean energy, and stock market risk. Expect deep dives, case analysis, and sharp insights into financial reportin...

Dive into the explosive Ostin Technology Group $OST case as we break down an alleged billion dollar pump and dump scheme, shareholder lawsuit, and federal charges. This episode is for retail investors, traders, and anyone interested in stock market fraud, securities litigation, and financial news. Expect deep dives, real case analysis, and engaging discussion on market manipulation and investor ri...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PYPL PayPal and its ambitious Branded Checkout growth targets. We examine Investor Day projections, twenty percent plus long term earnings goals, Venmo and buy now pay later expansion, slowing transaction payment volume growth, withdrawal of twenty twenty seven guidance, the CEO...

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $RGNX REGENXBIO and its RGX 111 gene therapy for Hurler syndrome. We break down Phase One Phase Two safety statements, no drug related serious adverse events messaging, Fast Track designation, the later FDA clinical hold after a central nervous system tumor finding, and the seventee...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $QURE uniQure and its AMT 130 gene therapy for Huntington disease. We examine the seventy five percent slowing claim, the Phase One Phase Two trial using an external control from ENROLL HD, the Biologics License Application timeline, the FDA reversal on study alignment, the three...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $KD Kyndryl and alleged misstatements about internal controls over financial reporting. We examine IT general control weaknesses, cash flow misstatements, the late Form 10 Q filing, SEC Division of Enforcement inquiry, executive departures, and the fifty five percent stock drop t...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $INO Inovio Pharmaceuticals and its accelerated approval hopes for INO 3107 and the CELLECTRA device. We examine the Biologics License Application delay, manufacturing issues, FDA standard review decision, stock offerings, and the twenty four percent stock drop that followed. Thi...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PSFE Paysafe and alleged undisclosed concentration risk in its ecommerce business. We examine revenue guidance, credit loss reserves, chargebacks tied to a high risk merchant, Merchant Category Code exposure, sponsor bank pressure, and the twenty seven percent stock drop that fo...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $TCPC BlackRock TCP Capital and alleged misstatements about net asset value, portfolio health, and non accrual investments. We examine NAV declines from ten dollars to near seven dollars, rising unrealized losses, restructuring efforts, and the sharp stock drops that followed. Th...

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $MREO Mereo BioPharma and its Phase Three ORBIT and COSMIC trials for setrusumab in osteogenesis imperfecta. We break down Phase Two bone mineral density data, missed fracture reduction endpoints, interim analysis results, the eighty seven percent stock collapse, and alleged mislead...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RARE Ultragenyx and its Phase Three Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta. We examine bone mineral density gains, failed fracture reduction endpoints, interim analysis results, the forty two percent stock drop, and alleged misleading statements about...

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $ORCL Oracle and its massive artificial intelligence infrastructure expansion. We break down ballooning capital expenditures from twenty five billion to fifty billion dollars, negative free cash flow, two hundred forty eight billion dollars in lease commitments, insider stock sales,...

In this episode of Sue Wall Street Holding Wall Street Accountable, we unpack the securities class action involving $PLUG Plug Power and its one billion six hundred sixty million dollar Department of Energy loan guarantee. We break down hydrogen production plans, the Texas facility, capital raises, executive departures, liquidity pivots, and the stock drops that followed. This deep dive is for ret...

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $PMI Picard Medical and its low float IPO, extreme stock volatility, and alleged social media stock promotion scheme. We break down the four dollar IPO, the rapid surge above thirteen dollars, the seventy percent collapse, WhatsApp trading groups, micro cap manipulation risks, and R...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RR Richtech Robotics and its headline making Microsoft AI collaboration. We analyze the press release language, the forty four percent stock surge, the thirty eight million dollar private placement, Microsoft’s denial of a commercial partnership, and the sharp stock drop that fo...

In this episode of Sue Wall Street Holding Wall Street Accountable, we investigate the securities class action surrounding $METC Ramaco Resources and its rare earth minerals pivot at the Brook Mine. We break down the ribbon cutting event, alleged lack of mining activity, drone footage claims, SEC filings, stock drop, and Rule 10b5 allegations. This deep dive is for retail investors, traders, and a...

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action surrounding $BYND Beyond Meat and its alleged asset impairment and disclosure issues. We explore EBITDA goals, non cash impairment charges, SEC filings, stock drops, and what it all means for shareholders. This deep dive is for retail investors, traders, and anyone interested in stock mark...

In this episode of Sue Wall Street Holding Wall Street Accountable we break down the explosive class action lawsuit against BellRing Brands Inc $BRBR the company behind Premier Protein. This podcast is for investors shareholders and anyone curious about stock market lawsuits securities fraud and corporate accountability. We dive deep into alleged misrepresentations inventory stockpiling hidden dem...

$SDM Smart Digital Group rocketed from $4 to nearly $30 per share then crashed over 85% amid allegations of a massive market manipulation scheme. In this episode of Sue Wall Street: Holding Wall Street Accountable, we expose how fake advisors, WhatsApp hype, and crypto buzz drove a meteoric rise… and a brutal collapse. If you're into IPO scams, SEC drama, and investor deception this one’s for you....

$VTGN Vistagen Therapeutics hyped its anxiety drug fasedienol as a game-changer but when the Phase 3 trial failed, the stock plummeted 80% in one day. In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the lawsuit accusing $VTGN of misleading investors with overly optimistic projections while hiding known risks tied to flawed trial design. If you're into biotech dra...

$CRWV CoreWeave rocketed 349% after its IPO, fueled by AI hype and a $11.9B OpenAI deal. But when delayed data centers, rainy Texas weather, and missed guidance hit, the stock cratered and now they’re facing a class action lawsuit. In this episode of Sue Wall Street: Holding Wall Street Accountable, we unpack the allegations of securities fraud, infrastructure failure, and inflated projections tha...

$BBWI Bath & Body Works touted its bold pivot "adjacencies, collaborations, and promotions" as the key to growth. But a class action lawsuit now claims that strategy masked core business struggles, ultimately leading to a 25% stock drop. In this episode of Sue Wall Street: Holding Wall Street Accountable, we dive into what investors were told, what was allegedly left out, and why this fragranc...

$ARDT Ardent Health pitched precision and transparency in its IPO but behind the scenes, it was relying on a flawed accounting method that allegedly overstated revenue by $43M and masked malpractice risks with underfunded reserves. In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the class action accusing $ARDT of inflating its value with outdated assumptions and mis...

$FFIV F5, Inc. told investors they offered “best-in-class” cybersecurity while hackers allegedly had long-term access to their top revenue-generating product. In this episode of Sue Wall Street: Holding Wall Street Accountable, we unpack the class action lawsuit claiming $FFIV concealed a serious security breach for over two months, misleading shareholders and triggering a double-digit stock drop....

$VRNS Varonis Systems told investors their cloud transition was smooth sailing until the stock crashed nearly 49% overnight. In this episode of Sue Wall Street: Holding Wall Street Accountable, we dig into the class action lawsuit alleging executives misled shareholders while renewal rates crumbled and SaaS conversions stalled. If you're into cybersecurity, tech drama, or Wall Street accountabilit...